A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
News
